BridgeBio Oncology Therapeutics, Inc. (BBOT) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of BridgeBio Oncology Therapeutics, Inc. stock $1.89, price $1.81, upside +4.4%, quality 33 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
BridgeBio Oncology Therapeutics, Inc.
BBOT · USThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.
How to read this chart
15‑month range $1.81 – $13.73 · fair‑value band $1.42 – $2.36 · the $1.81 price screens below the $1.89 fair value. As of Nov 20, 2026.
Every Wednesday you see whether BridgeBio Oncology Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Show moreShow less
The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.
The company was incorporated in 2016 is headquartered in South San Francisco, California.
Stock analysis
BridgeBio Oncology Therapeutics, Inc. (BBOT) currently trades at $1.81, while our estimate is $1.89, so the stock looks roughly fairly valued today (gap 4.2%).
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.42 (bear) to $2.36 (bull), the price of $1.81 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
BridgeBio Oncology Therapeutics, Inc. reported revenue of $0 in FY2025 versus $0 in FY2023. Reported net income was −$134M in FY2025.
Key figures
Market cap $189M Micro · P/E ratio 3.4 · EPS (TTM) $0.53 · Return on equity −46.4% · Return on assets (EBIT) −3,913% (5-year average) · Free cash flow −$115M · Net cash $371M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 87% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at 4%, BBOT screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 2 officers or directors sold shares worth $3,628 and none bought.
- SalePedro BeltranPresident and CEO, Director1,870 shares at $1.84$3,443Nov 18, 202610b5-1 plan
- SaleMarc CoboPrincipal Accounting Officer78 shares at $2.37$185Nov 13, 202610b5-1 plan
Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 20, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch BBOT, get fair value alerts →
Compare BridgeBio Oncology Therapeutics, Inc. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $920.69 | $1,275.02 | +38% | vs BBOT |
| Vertex Pharmaceuticals Incorporated VRTX | $515.02 | $587.62 | +14% | vs BBOT |
| Samsung Biologics Co 207940 | ₩1,355,000 | ₩1,512,500 | +12% | vs BBOT |
| argenx SE ARGX | $925.70 | $908.40 | −2% | vs BBOT |
| CSL Limited CSL | A$197.29 | A$188.80 | −4% | vs BBOT |
| BeOne Medicines AG 6160 | HK$230.80 | HK$152.92 | −34% | vs BBOT |
| Moderna, Inc MRNA | $195.00 | $122.98 | −37% | vs BBOT |
| Revolution Medicines, Inc RVMD | $161.20 | $83.12 | −48% | vs BBOT |
| Celltrion, Inc 068270 | ₩213,000 | ₩74,574 | −65% | vs BBOT |
| Royalty Pharma plc RPRX | $68.45 | $19.01 | −72% | vs BBOT |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) overvalued or undervalued?
What is the fair value of BBOT?
What is the quality score of BBOT?
What is the price target for BridgeBio Oncology Therapeutics, Inc. (BBOT)?
What is the BridgeBio Oncology Therapeutics, Inc. stock forecast for 2026?
What is the intrinsic value of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
Is BridgeBio Oncology Therapeutics, Inc. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of BBOT?
How much is BridgeBio Oncology Therapeutics, Inc. worth?
What do the bullish and bearish scenarios say about BBOT?
What is the P/E ratio of BBOT?
How solid is the balance sheet of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
How far is BBOT from its 52-week high?
Which stocks are comparable to BridgeBio Oncology Therapeutics, Inc.?
Is BridgeBio Oncology Therapeutics, Inc. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
What should I pay attention to with BridgeBio Oncology Therapeutics, Inc. right now?
Key figures of BridgeBio Oncology Therapeutics, Inc.
How large is the market capitalisation of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
What are the earnings per share of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
What is the return on equity of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
What is the EBIT return on assets of BridgeBio Oncology Therapeutics, Inc. (BBOT)?
How much free cash flow does BridgeBio Oncology Therapeutics, Inc. (BBOT) generate?
How much net cash does BridgeBio Oncology Therapeutics, Inc. (BBOT) hold?
Watch BridgeBio Oncology Therapeutics, Inc. in the live analysis
One click puts BridgeBio Oncology Therapeutics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.